The Reply to the letter on the cost-effectiveness of human papillomavirus in Punjab further distorts the scientific record

Cancer. 2018 Mar 1;124(5):1085. doi: 10.1002/cncr.31167. Epub 2017 Nov 22.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adolescent
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Immunization Programs
  • India
  • Papillomaviridae*
  • Papillomavirus Infections*
  • Papillomavirus Vaccines*
  • Vaccination

Substances

  • Papillomavirus Vaccines